FDA Inspection 1067103 — HQ Specialty Pharma
The FDA completed an inspection of HQ Specialty Pharma on Sep 7, 2018 in Paramus, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 7, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Paramus, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)